Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Bicycle Therapeutics plc reported revenue of $73M, up 105.8% year over year. Operating margin was -340.4% and net margin -301.7%, on a free-cash-flow margin of -347.2% with capital expenditure at 3.2% of revenue. Every figure is computed directly from BCYC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $73M | -340.4% | -301.7% |
| FY2024 | $35M | -595.0% | -479.2% |
| FY2023 | $27M | -704.1% | -669.7% |
| FY2022 | $14M | -806.6% | -779.3% |
| FY2021 | $12M | -561.0% | -571.2% |
How does BCYC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.